IRIDEX Corporation (IRIX) - Cash Flow Conversion Efficiency
Based on the latest financial reports, IRIDEX Corporation (IRIX) has a cash flow conversion efficiency ratio of 0.048x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($174.00K) by net assets ($3.64 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see IRIDEX Corporation (IRIX) market capitalisation for the company's overall valuation and market capitalisation.
IRIDEX Corporation - Cash Flow Conversion Efficiency Trend (1995–2025)
This chart illustrates how IRIDEX Corporation's cash flow conversion efficiency has evolved over time, based on yearly financial data.
IRIDEX Corporation Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of IRIDEX Corporation ranked by their cash flow conversion efficiency. Explore IRIX cash flow quality index to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
ECSTELECOM Co. Ltd
KQ:067010
|
0.056x |
|
Pasithea Therapeutics Corp
NASDAQ:KTTA
|
-0.237x |
|
Cahayaputra Asa Keramik Tbk PT
JK:CAKK
|
0.138x |
|
Nam Sung
KO:004270
|
-0.009x |
|
Miliboo SA
PA:ALMLB
|
0.126x |
|
Gaming Corps AB
ST:GCOR
|
0.791x |
|
Greenland Hong Kong Holdings Limited
F:QFRA
|
-0.007x |
|
Prairie Provident Resources Inc
TO:PPR
|
0.100x |
Annual Cash Flow Conversion Efficiency for IRIDEX Corporation (1995–2025)
The table below shows the annual cash flow conversion efficiency of IRIDEX Corporation from 1995 to 2025. View IRIX live share price for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $4.92 Million | $-2.12 Million | -0.430x | +87.63% |
| 2024-12-31 | $2.10 Million | $-7.29 Million | -3.474x | -390.43% |
| 2023-12-31 | $9.52 Million | $-6.75 Million | -0.708x | -28.23% |
| 2022-12-31 | $17.23 Million | $-9.52 Million | -0.552x | -256.64% |
| 2021-12-31 | $23.30 Million | $8.22 Million | 0.353x | +289.21% |
| 2020-12-31 | $17.37 Million | $-3.24 Million | -0.186x | +46.52% |
| 2019-12-31 | $22.70 Million | $-7.91 Million | -0.349x | -4.16% |
| 2018-12-31 | $29.96 Million | $-10.03 Million | -0.335x | -186.47% |
| 2017-12-31 | $30.52 Million | $-3.56 Million | -0.117x | -3076.34% |
| 2016-12-31 | $39.16 Million | $-144.00K | -0.004x | +79.11% |
| 2015-12-31 | $33.69 Million | $-593.00K | -0.018x | -114.79% |
| 2014-12-31 | $33.74 Million | $4.01 Million | 0.119x | +301.07% |
| 2013-12-31 | $25.85 Million | $767.00K | 0.030x | +246.69% |
| 2012-12-31 | $21.91 Million | $-443.00K | -0.020x | -114.88% |
| 2011-12-31 | $22.43 Million | $3.05 Million | 0.136x | -24.10% |
| 2010-12-31 | $19.43 Million | $3.48 Million | 0.179x | -60.42% |
| 2009-12-31 | $15.03 Million | $6.80 Million | 0.452x | +5635.50% |
| 2008-12-31 | $11.75 Million | $-96.00K | -0.008x | +70.55% |
| 2007-12-31 | $18.81 Million | $-522.00K | -0.028x | +35.57% |
| 2006-12-31 | $32.16 Million | $-1.39 Million | -0.043x | -153.67% |
| 2005-12-31 | $34.52 Million | $2.77 Million | 0.080x | +230.82% |
| 2004-12-31 | $31.78 Million | $771.00K | 0.024x | -85.34% |
| 2003-12-31 | $30.83 Million | $5.10 Million | 0.165x | +98.40% |
| 2002-12-31 | $30.20 Million | $2.52 Million | 0.083x | +168.46% |
| 2001-12-31 | $29.83 Million | $-3.63 Million | -0.122x | -4921.99% |
| 2000-12-31 | $30.50 Million | $-74.00K | -0.002x | -102.33% |
| 1999-12-31 | $27.50 Million | $2.86 Million | 0.104x | +234.75% |
| 1998-12-31 | $25.90 Million | $-2.00 Million | -0.077x | -1745.56% |
| 1997-12-31 | $23.90 Million | $-100.00K | -0.004x | +93.08% |
| 1996-12-31 | $21.50 Million | $-1.30 Million | -0.060x | -131.58% |
| 1995-12-31 | $4.70 Million | $900.00K | 0.191x | -- |
About IRIDEX Corporation
IRIDEX Corporation, an ophthalmic medical technology company, provides therapeutic based laser systems, delivery devices, and consumable instrumentation to treat sight-threatening eye diseases in ophthalmology. It offers laser consoles, such as Cyclo G6 laser system for use in the treatment of glaucoma; IQ 532 and IQ 577 laser systems, which are used for the treatment of retinal disorders; and Oc… Read more